MedTrace Logo

AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19

NCT04649775 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2022-11-25

Study results available
· View outcomes & findings →

Summary

The study is an unblinded, randomized, controlled trial for use of the AirFlO2 device for patients admitted to Duke Hospital with COVID-19 and tachypnea (RR \>20 breaths/min) and/or hypoxia (Oxygen saturation \<94% on room air or requiring supplemental oxygen at baseline).

Conditions

  • Corona Virus Infection
  • Respiratory Rate
  • Hypoxia
  • Covid19

Interventions

DEVICE

AirFLO2

Mask device

Sponsors & Collaborators

Principal Investigators

  • Loretta Que, MD · Duke Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-09
Primary Completion
2021-11-08
Completion
2021-11-08
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04649775 on ClinicalTrials.gov